Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19533902 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL4561370 | 0.89 | ALDH1A1 (0.39) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL8884810 | 0.89 | ALDH1A1 (0.39) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL24439064 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL29674209 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL3393707 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL24439068 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL29674118 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL3839504 | 0.82 | SLC18A3 (0.44) | ALDH1A1TSHRCHRM2OPRM1DDB1 | |
| SCHEMBL5422025 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TSHRCHRM2OPRM1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-02 | — | — | US | disclosed |
| WO-2017189661-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-02 | — | — | WO | disclosed |
| EP-0676960-B1 | CYCLOALKYL AMINE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-0676960-A4 | — | — | 1995-11-15 | — | — | EP | disclosed |
| EP-0676960-A1 | CYCLOALKYL AMINE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5451596-A | Cycloalkyl amine bis-aryl squalene synthase inhibitors | RHONE POULENC RORER PHARMACEUTICALS INC. (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1994014435-A1 | CYCLOALKYL AMINE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313691-A1 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | RORC, RORA, RORB | ALDH1A1 171/4885TSHR 258/4885CHRM2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.